Gina M. Mantia-Smaldone, MD
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111
Video: Gina Mantia-Smaldone, MD
Attending Surgeon, Gynecologic Oncology
Department of Surgical Oncology, Division of Gynecologic Oncology
Meet other members of the gynecological cancer treatment team.
Minimally Invasive Surgery (Laparoscopy and Robotic Surgery), Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer and Hyperplasia, Uterine Sarcoma, Cervical Cancer and Dysplasia, Vulvar Cancer and Dysplasia, Vaginal Cancer and Dysplasia, Gestational Trophoblastic Disease, Surgical Management of Pelvic Masses
Certifications:American Board of Obstetrics and Gynecology (eligible)
I am excited to join the Gynecologic Cancer Patient Care Team at the Fox Chase Cancer Center. I chose to work at Fox Chase where I can provide comprehensive, cutting-edge oncologic care by translating advances in research directly into my clinical practice.
As a Gynecologic Oncologist, I specialize in the surgical and medical management of tumors of the uterus, cervix, ovary, fallopian tube, vulva and vagina. I have extensive experience with complex open, laparoscopic and robotic surgery, which allows me to tailor a surgical plan based upon a patient’s needs and preferences. I also have expertise in administering intravenous and intraperitoneal chemotherapy for gynecologic malignancies. As a member of the multi-disciplinary Gynecologic Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance of cure for each patient.
I appreciate the challenges and commitment necessary to care for cancer patients. I understand that a cancer diagnosis can be overwhelming for patients and their families, and I always treat patients how I would want my family members to be treated: with honesty and compassion. I devote the time necessary to educate my patients on their options so that they are best able to make an informed decision about their treatment.
Professionally, my research interests focus on endometriosis-associated ovarian cancer and hereditary ovarian cancer, including those resulting from BRCA1 or 2 mutations. The abundant resources available at the Fox Chase Cancer Center as well as my research experiences during my Postdoctoral Fellowship at the Magee-Womens Research Institute and as a Clinical Fellow at the University of Pennsylvania allow for me to participate in translational research and to investigate innovative therapies to improve the quality of life for women suffering from gynecologic malignancies.
Medical EducationMD, State University of New York at Stony Brook School of Medicine, Stony Brook, New York, 2004
ResidenciesObstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, 2004-2008
Postdoctoral Fellowship in Ovarian Cancer Immunology, Division of Gynecologic Oncology, Magee-Womens Research Institute/University of Pittsburgh, Pittsburgh, PA, 2008-2010;
Clinical Fellow, Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2010-2013
American College of Obstetrics and Gynecology
American Association for Cancer Research
Society of Gynecologic Oncologists
Dr. Mantia-Smaldone on PubMed
Mantia Smaldone G, Richard S, Krivak T, Kelley J and Edwards R. Pregnancy After Tumor Debulking and Intraperitoneal Cisplatin for Appendiceal Carcinoid Tumor. Obstet Gynecol. 2007 Aug; 110 (2 Pt 2): 477-9.
Alperin M, Mantia-Smaldone G and Sagan E. Conservative Management of Postoperatively Diagnosed Cystotomy: a case series. Urology. 2009 May; 73(5):1163.e17-9. Epub 2008 Jun 2
Dhupar R, Smaldone GM and Hamad GG. Is there a benefit to delaying cholecystectomy for symptomatic gallbladder disease during pregnancy? Surg Endosc. 2010 Jan; 24(1):108-12. Epub 2009 Jun 11.
Mantia Smaldone G, Krohn M and McGee E. Cervical Cancer and Risk for Delivery of Small-for-Gestational Age Neonates. J Womens Health (Larchmt). 2010 May; 19(5):969-74.
Mantia Smaldone GM, Richard SD and Edwards RP. Pregnancy outcomes after conservative surgical management of ovarian neoplasms treated at a single institution. Int J Gynecol Cancer. 2010 Aug; 20(6):926-31.
Mantia-Smaldone G*, Budiu R*, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP and Vlad AM. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother. 2011 Jul: 60 (7): 975-84. 2011 Jul; 60(7):975-84. doi: 10.1007/s00262-011-1010-x. Epub 2011 Apr 2. (*Both authors contributed equally to this work).
Mantia-Smaldone GM, Edwards RP and Vlad AM. Targeted treatment of recurrent platinum resistant ovarian cancer: current and emerging therapies. Cancer Management and Research. 2011(3): 25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.
Mantia-Smaldone G, Corr B and Chu CS. Immunotherapy in Ovarian Cancer. Human Vaccines & Immunotherapeutics. 2012 Sep 1; 8(9). 2012 Sep; 8(9):1179-91. doi: 10.4161/hv.20738. Epub 2012 Aug 21.
Suryawanshi S, Vlad AM, Lin H, Mantia-Smaldone G, Laskey R, Lee M, Lin Y, Donnellan N, Klein-Patel M, Lee T, Mansuria S , Elishaev E, Budiu R, Edwards R, and Huang X. Plasma microRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer. Clin Cancer Res. 2013 Mar 1; 19(5): 1213-24.
Mantia-Smaldone GM and Chu CS. A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges. BioDrugs. 2013 Apr 17. [Epub ahead of print]
Corr B, Mantia-Smaldone G, Cantor J, Livolsi V and Chu CS. Metastatic Cholangiocarcinoma to the Ovary: A Case Series. Accepted September 25, 2012 for publication in International Journal of Gynecological Pathology.
Mantia-Smaldone G, Bagley LJ, Kasner SE and Chu CS. Vertebral artery dissection and cerebral infarction in a patient with recurrent ovarian cancer receiving bevacizumab. Accepted March 3, 2013 for publication in Gynecologic Oncology Case Reports.
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P and Adams SF. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficienct ovarian tumors and can be exploited to improve treatment response in a mouse model. Submitted April 15, 2013 for publication in Gynecologic Oncology.
Chiang CL, Kandalaft L, Tanyi J, Hagemann A, Motz G, Svoronos N, Smith L, Montone K, Mantia-Smaldone G, Nisenbaum H, Torigian D, Levine B, Mick R, Kalos M, Czerniecki B, Powell D, and Coukos G. A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clin Cancer Res. 2013 Jul 9 [Epub ahead of print]
Mantia-Smaldone GM and Scholler N. Preventive Strategies in Epithelial Ovarian Cancer. Ovarian Cancer –Clinical and Therapeutic Perspectives. Editor Samir A. Farghaly. InTech Open Access. ISBN 978-953-307-810-6. February 2, 2012: 15-42.
Selected Invited Presentations:
2007 ACOG District III meeting, Philip F. Williams Prize paper, “Women with a History of Cervical Cancer Are at Risk of Delivering Small for Gestational Age Infants in a Future Pregnancy.” Santo Domingo, DR
2009 Mid Atlantic Gynecologic Oncology Society, “Oncologic Outcomes in Reproductive-Age Women with Grade 1 Early Stage Epithelial Ovarian Cancer.” Hot Springs, VA
2009 Mid Atlantic Gynecologic Oncology Society, “Serous versus Mucinous Low Malignant Potential Ovarian Tumors in Reproductive-Age Women.” Hot Springs, VA
2011 Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer, “BRCA1 deficient tumors demonstrate enhanced cytotoxicity and T cell recruitment following Doxil treatment.” Orlando, FL.
2012 Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer, “CD8 T cell-mediated immune responses are critical to the increased efficacy of Doxil in BRCA1 deficient tumors.” Austin, TX
2013 University of Pennsylvania Center for Research on Reproduction and Women’s Health annual retreat, “The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1-deficienct ovarian tumors and can be exploited to improve treatment response in a mouse model.” Philadelphia, PA